ReviewExperimental and molecular pathology2009
Combined yeast-derived beta-glucan with anti-tumor monoclonal antibody for cancer immunotherapy.
Review in Experimental and molecular pathology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 75 citations in OpenAlex.
- Oral Intake of Carboxymethyl-Glucan (CM-G) from Yeast (Saccharomyces uvarum) Reduces Malondialdehyde Levels in Healthy Men.Molecules (Basel, Switzerland) · 2015Trial
- Natural polysaccharides as multifunctional anti-cancer agents: structure-activity relationships, mechanisms of action, and therapeutic potential.Frontiers in immunology · 2026Review
- The role of gut mycobiome in responses to cancer immunotherapy.Gut microbes · 2025Review
- Review
- Yeast-fermented feed improves high-concentrate diet-induced mastitis in dairy goats by regulating rumen microbiota.Frontiers in microbiology · 2025Article
- The Efficacy of Yeast Supplementation on Monogastric Animal Performance-A Short Review.Life (Basel, Switzerland) · 2023Review
- The role of neutrophils in trained immunity.Immunological reviews · 2023Review
- Fungal Mushrooms: A Natural Compound With Therapeutic Applications.Frontiers in pharmacology · 2022Review
- Postbiotics, Metabolic Signaling, and Cancer.Molecules (Basel, Switzerland) · 2021Review
- Potential benefit of β-glucans as adjuvant therapy in immuno-oncology: a review.Exploration of targeted anti-tumor therapy · 2021Review
- Article
- B-glucans from Grifola frondosa and Ganoderma lucidum in breast cancer: an example of complementary and integrative medicine.Oncotarget · 2018Review
- Autocrine Type I IFN Signaling in Dendritic Cells Stimulated with Fungal β-Glucans or Lipopolysaccharide Promotes CD8 T Cell Activation.Journal of immunology (Baltimore, Md. : 1950) · 2017Article
- Extracellular polysaccharides from Ascomycota and Basidiomycota: production conditions, biochemical characteristics, and biological properties.World journal of microbiology & biotechnology · 2015Review
- Dectin-1 Activation by a Natural Product β-Glucan Converts Immunosuppressive Macrophages into an M1-like Phenotype.Journal of immunology (Baltimore, Md. : 1950) · 2015Article
- Particulate β-glucan regulates the immunosuppression of granulocytic myeloid-derived suppressor cells by inhibiting NFIA expression.Oncoimmunology · 2015Article
- Identification of Wild Yeast Strains and Analysis of Their β-Glucan and Glutathione Levels for Use in Makgeolli Brewing.Mycobiology · 2014Article
- Exopolysaccharide from Ganoderma applanatum as a promising bioactive compound with cytostatic and antibacterial properties.BioMed research international · 2014Article
- Structure elucidation and immunomodulatory activity of a beta glucan from the fruiting bodies of Ganoderma sinense.PloS one · 2014Article
- Immunostimulatory properties and antitumor activities of glucans (Review).International journal of oncology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Beta-glucan is an immuno-stimulating agent that has been used to treat cancer and infectious disease for many years with varying and unpredictable efficacy. Recent studies have unraveled the action mode of yeast-derived beta-glucan in combination with anti-tumor monoclonal antibodies (mAbs) in cancer therapy. It has demonstrated that particulate or large molecular weight soluble beta-glucans are ingested and processed by macrophages. These macrophages secrete the active moiety that primes neutrophil complement receptor 3 (CR3) to kill iC3b-opsonized tumor cells. In vitro and in vivo data demonstrate that successful combination therapy requires complement activation and deposition on tumors and CR3 expression on granulocytes. Pre-clinical animal studies have demonstrated the efficacy of combined beta-glucan with anti-tumor mAb therapy in terms of tumor regression and long-term survival. Clinical trials are underway using anti-epidermal growth factor receptor mAb (cetuximab) in combination with beta-glucan for metastatic colorectal cancer. This review provides a brief overview of this combination therapy in cancer and describes in detail the beta-glucan composition and structure, mechanism of action, and preclinical studies in human carcinoma xenograft models. It is proposed that the addition of beta-glucan will further improve the therapeutic efficacy of anti-tumor mAbs in cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.